ITT Corp. has signed a long-term supply agreement with oncology company Novocure to help produce a powerful new weapon against an aggressive, recurrent brain cancer called glioblastoma multiforme (GBM). As part of the new solution, which was recently approved by the U.S. Food and Drug Administration, ITT has adapted its piezoelectric ceramic technology to produce disks that radiate a low-intensity, alternating electric field. The technology slows and reverses tumor growth by inhibiting mitosis, the process by which cells divide and replicate.
“We have been partnering with Novocure for several years to develop, refine and produce this innovative solution,” said Chris Bernhardt, president of ITT Electronic Systems. “We are elated that ITT defense technology will play a significant role in successfully treating one of the most aggressive forms of cancer.”
GBM is the most aggressive and common form of primary brain cancer in the U.S., affecting approximately 10,000 Americans each year. Working closely with Novocure as one of its key suppliers in this effort, ITT’s goal was to ensure the technology’s design was producible and effective so it could be a viable option for combating this deadly disease.
“We have been shipping 40,000 ceramic disks a month-more than 1 million total-to support clinical trials,” said Bernhardt. “Going forward, we have the capacity to meet Novocure’s emerging needs to ensure that patients who need this treatment will have access to it.”
For more information, visit www.itt.com